You are here: Industry Insights > BrainStorm

News List

BrainStorm, Catalent Complete Tech Transfer for NurOwn contractpharma
December 08, 2021
Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.
BrainStorm Announces Positive Topline Data in NurOwn Study for Progressive MS americanpharmaceuticalreview
March 30, 2021
BrainStorm Cell Therapeutics announced topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS).
BrainStorm Receives FDA Feedback on ALS Clinical Development Program americanpharmaceuticalreview
February 25, 2021
BrainStorm Cell Therapeutics recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial.
Catalent, BrainStorm Enter ALS Drug Manufacturing Pact contractpharma
October 23, 2020
Catalent will undertake the transfer of the manufacturing process to, and provide future cGMP clinical supply of NurOwn from its Houston facility.
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update prnewswire
October 16, 2020
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the third quarter ended September 30, 2020, and provided a corporate update.
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn for Alzheimer's Disease americanpharmaceuticalreview
July 03, 2020
BrainStorm Cell Therapeutics announced a new clinical program focused on the development of NurOwn® as a treatment for Alzheimer's disease.
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study firstwordpharma
February 23, 2019
MS is a chronic neuroinflammatory and neurodegenerative disorder that affects the brain and spinal cord. MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide.
FDA Accepts BrainStorm’s NurOwn IND Application for Progressive Multiple Sclerosis americanpharmaceuticalreview
December 19, 2018
BrainStorm Cell Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to.....
BrainStorm mulls making ‘modest profits’ from providing unproven cell therapy on a right-to-try basis fiercebiotech
June 25, 2018
BrainStorm Cell Therapeutics is considering providing an experimental therapy to amyotrophic lateral sclerosis (ALS) patients under the recently passed U.S
BrainStorm Announces NurOwn Phase 3 Trial Agreements pharmaceutical-technology
July 20, 2017
BrainStorm Cell Therapeutics has signed definitive agreements with Massachusetts General Hospital and California Pacific Medical Center (CPMC) to enroll patients in the planned Phase 3 clinical trial of NurOwn in amyotrophic lateral sclerosis (ALS),